Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20261020031
- Term of Validity
- 20 October 2026 - 20 October 2027
- Company's Country
- United Kingdom
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
General information
- Short Summary
- A UK biotechnology SME with a patented silica-based biomolecule stabilisation platform seeks to join Horizon Europe consortia for HORIZON-HLTH-2027-01-DISEASE-05, -06 and -07. The company is interested in supporting antibodies, peptides, conjugates and other therapeutic modalities through stabilisation, formulation and delivery-related R&D. Research Co-operation Agreement sought.
- Full Description
-
A UK biotechnology SME has developed a patented silica-based platform technology for improving the stability and handling of temperature-sensitive biomolecules and biopharmaceutical products. The company seeks to participate in European collaborative R&D projects as a specialist consortium partner and does not intend to act as project coordinator.
The technology protects thermally unstable biomolecules within a tailored silica matrix, helping to preserve structural and functional integrity during storage and transport. It is designed for both existing and newly developed biopharmaceutical formulations and has applications across antibodies, vaccines, enzymes, genetic material and other biomolecules. The platform is designed to reduce reliance on refrigerated or frozen storage and does not depend on lyophilisation or similarly harsh processing conditions. Published company data reports protection across temperatures from approximately -80°C to +50°C.
The SME has experience applying its technology in collaborative biopharmaceutical development programmes, including international vaccine-development activity and current UK-funded work integrating its stabilisation technology into a monoclonal-antibody manufacturing process.
Its current collaboration interests are focused particularly on antibodies, peptides and conjugated therapeutics, alongside other relevant therapeutic modalities where its stabilisation, formulation or delivery-related expertise could make a meaningful contribution.
The company is interested in two complementary areas of R&D: stabilisation and formulation of therapeutic candidates, including approaches intended to improve product robustness and reduce cold-chain requirements; and formulation linked to mode of administration, including subcutaneous and oral administration where relevant to the candidate and project objectives.
Within collaborative projects, the SME can contribute specialist expertise in biomolecule stabilisation, formulation and product-development activities, with the precise role tailored to the therapeutic modality, development stage and requirements of the wider consortium.
The company is particularly interested in consortia preparing proposals for:
- HORIZON-HLTH-2027-01-DISEASE-05 - Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- HORIZON-HLTH-2027-01-DISEASE-06 - Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- HORIZON-HLTH-2027-01-DISEASE-07 - Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
For DISEASE-06 and DISEASE-07, the strongest alignment is with consortia progressing monoclonal-antibody candidates where stabilisation, formulation, manufacturability and product presentation form part of the translational pathway. For DISEASE-05, the SME is open to discussions with consortia developing eligible small-molecule antiviral programmes where its technology and expertise can make a technically justified contribution, particularly in addressing challenges relating to formulation science, product stability or administration.
The SME seeks to complement multidisciplinary consortia through a defined specialist technical contribution rather than overall project coordination. Collaboration is envisaged under a Research Co-operation Agreement. - Advantages and Innovations
-
The SME’s patented silica-based technology provides an alternative approach to stabilising biomolecules. The platform is designed to protect biologics from aggregation and thermal degradation while reducing reliance on refrigerated or frozen storage and transport.
The company states that the technology can protect thermally unstable biomolecules across temperatures from approximately –80°C to +50°C and, unlike conventional lyophilisation-based approaches, does not rely on freeze-drying or other harsh processing conditions.
The platform is designed for use with both existing and newly developed biopharmaceutical formulations, allowing it to be considered across a range of biological product types.
The key potential advantages are:
• reduced dependence on cold-chain storage and transport;
• protection of sensitive biomolecules across a broad temperature range;
• avoidance of lyophilisation-based processing;
• applicability to different biopharmaceutical formulations;
• potential to support more flexible formulation and product-development strategies;
• reduced per batch manufacturing costs vs lyophilisation-based processing;
• lower class 2 emissions.
The SME combines the platform technology with multidisciplinary in-house expertise spanning antibody manufacturing and process development, vaccine development, biomolecule purification, medicinal chemistry, cellular and molecular biology and in-vitro evaluation. The team operates from laboratory facilities in a UK life-sciences innovation environment, supporting ongoing optimisation and development of the stabilisation platform. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 12: Responsible Consumption and Production
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- IPR granted
- IPR notes
- The core silica-based stabilisation platform is patent protected. Further information can be shared with prospective partners subject to appropriate confidentiality arrangements.
Partner Sought
- Expected Role of a Partner
-
The SME seeks coordinators and lead partners forming multidisciplinary consortia for HORIZON-HLTH-2027-01-DISEASE-05, HORIZON-HLTH-2027-01-DISEASE-06 and HORIZON-HLTH-2027-01-DISEASE-07.
Potential partners may include universities and research institutes, biotechnology and pharmaceutical companies, translational research organisations, clinical centres, organisations leading Horizon Europe collaborative research projects in infectious diseases, biologics, antibody therapeutics, vaccine development or translational medicine, and other organisations with relevant capabilities in antiviral or biologic therapeutic development.
For DISEASE-06 and -07, particular interest is in consortia that already have a credible monoclonal-antibody candidate or established antibody-development programme and are assembling the complementary capabilities needed to progress the candidate through preclinical, manufacturing, regulatory and clinical development. Relevant capabilities may include disease-specific virology, antibody characterisation, preclinical models, GMP manufacturing, regulatory strategy, clinical development and access to relevant clinical or endemic/outbreak settings, where required by the project. The calls also encourage participation from organisations in countries where the targeted viruses are endemic or where outbreaks have occurred or are ongoing.
For DISEASE-05, the SME is interested in joining consortia with a credible small-molecule antiviral development programme where its technology and expertise can provide a technically relevant specialist contribution.
The SME does not seek to coordinate the overall project. It aims to participate as a specialist technology partner contributing a defined task or work package in biomolecule stabilisation, formulation or delivery-related development, with particular interest in antibodies, peptides and conjugated therapeutics.
The preferred consortium would combine a strong therapeutic asset or development programme with complementary expertise in disease biology, preclinical evaluation, manufacturing, regulatory strategy and clinical translation, while integrating the SME's specialist capabilities where they add value.
The intended outcome is for the SME to become an integrated technical partner within an international consortium, contributing its specialist platform and scientific expertise supporting the development and translation of therapeutic products through its specialist stabilisation, formulation and scientific expertise. Collaboration is envisaged under a Research Co-operation Agreement. - Type and Size of Partner
- SME 50 - 249
- SME <=10
- Big company
- SME 11-49
- R&D Institution
- University
- Other
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001024 - Medical Biomaterials
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05003001 - Therapeutic services
- Sector Groups Involved
- Health
- Targeted countries
- All countries